Businesses that began making hand sanitizers in response to the COVID-19 pandemic won’t pay US OTC drug monograph program facility fees but firms subject to the requirement will pay $6,000 more than initially was calculated.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?